Cargando…
Management of cognitive and negative symptoms in schizophrenia
Currently available antipsychotics provide only modest benefit in managing the cognitive and negative symptoms of schizophrenia even though these symptoms are often the most impairing in patients' daily lives. Certain antipsychotics may have slight benefits over others, and several nonpharmacol...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association of Psychiatric Pharmacists
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645289/ https://www.ncbi.nlm.nih.gov/pubmed/36405508 http://dx.doi.org/10.9740/mhc.2022.10.282 |
_version_ | 1784826934232875008 |
---|---|
author | Maroney, Megan |
author_facet | Maroney, Megan |
author_sort | Maroney, Megan |
collection | PubMed |
description | Currently available antipsychotics provide only modest benefit in managing the cognitive and negative symptoms of schizophrenia even though these symptoms are often the most impairing in patients' daily lives. Certain antipsychotics may have slight benefits over others, and several nonpharmacologic and pharmacologic adjunctive treatments have been evaluated in recent clinical trials. Recently published meta-analyses and clinical studies of such treatments are reviewed. Potential strategies to manage cognitive and negative symptoms, including deprescribing of medications that may exacerbate these symptoms, are described using theoretical case examples. |
format | Online Article Text |
id | pubmed-9645289 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Association of Psychiatric Pharmacists |
record_format | MEDLINE/PubMed |
spelling | pubmed-96452892022-11-18 Management of cognitive and negative symptoms in schizophrenia Maroney, Megan Ment Health Clin Psychopharmacology Pearls Currently available antipsychotics provide only modest benefit in managing the cognitive and negative symptoms of schizophrenia even though these symptoms are often the most impairing in patients' daily lives. Certain antipsychotics may have slight benefits over others, and several nonpharmacologic and pharmacologic adjunctive treatments have been evaluated in recent clinical trials. Recently published meta-analyses and clinical studies of such treatments are reviewed. Potential strategies to manage cognitive and negative symptoms, including deprescribing of medications that may exacerbate these symptoms, are described using theoretical case examples. American Association of Psychiatric Pharmacists 2022-11-03 /pmc/articles/PMC9645289/ /pubmed/36405508 http://dx.doi.org/10.9740/mhc.2022.10.282 Text en © 2022 AAPP. The Mental Health Clinician is a publication of the American Association of Psychiatric Pharmacists. https://creativecommons.org/licenses/by-nc/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Psychopharmacology Pearls Maroney, Megan Management of cognitive and negative symptoms in schizophrenia |
title | Management of cognitive and negative symptoms in schizophrenia |
title_full | Management of cognitive and negative symptoms in schizophrenia |
title_fullStr | Management of cognitive and negative symptoms in schizophrenia |
title_full_unstemmed | Management of cognitive and negative symptoms in schizophrenia |
title_short | Management of cognitive and negative symptoms in schizophrenia |
title_sort | management of cognitive and negative symptoms in schizophrenia |
topic | Psychopharmacology Pearls |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645289/ https://www.ncbi.nlm.nih.gov/pubmed/36405508 http://dx.doi.org/10.9740/mhc.2022.10.282 |
work_keys_str_mv | AT maroneymegan managementofcognitiveandnegativesymptomsinschizophrenia |